RESUMEN
We report a case of a 36-year-old man with a medical history of human immunodeficiency virus (HIV) infection who presented with hypomimia, hypophonia, bradykinesia, rigidity, and freezing of gait. His clinical presentation and magnetic resonance imaging were consistent with HIV encephalopathy with involvement of the bilateral basal ganglia and diffuse leukoencephalopathy. We initiated a trial of carbidopa-levodopa. The dose was escalated to 1050 mg levodopa daily. Amantadine was also started. The patient was closely monitored for behavioral, neurological, or systemic side effects. He tolerated therapy well without adverse effects. The patient's neurological status significantly improved with levodopa, including hypomimia, hypophonia, bradykinesia, and fluidity of gait. This case demonstrates that carbidopa-levodopa can be safely utilized to manage parkinsonism in an adult patient with HIV encephalopathy.
Asunto(s)
Complejo SIDA Demencia/tratamiento farmacológico , Amantadina/uso terapéutico , Antiparkinsonianos/uso terapéutico , Carbidopa/administración & dosificación , Trastornos Neurológicos de la Marcha/etiología , Hipocinesia/etiología , Levodopa/administración & dosificación , Adulto , Carbidopa/uso terapéutico , Combinación de Medicamentos , Humanos , Leucoencefalopatías , Levodopa/uso terapéutico , Masculino , Resultado del TratamientoAsunto(s)
Encefalitis/diagnóstico , Encefalitis/tratamiento farmacológico , Puente/patología , Esteroides/uso terapéutico , Linfocitos T , Ataxia/etiología , Calcio , Canales de Calcio Tipo Q , Enfermedad Crónica , Encefalitis/patología , Femenino , Humanos , Inflamación/diagnóstico , Inflamación/tratamiento farmacológico , Inflamación/patología , Persona de Mediana Edad , Síndrome , Linfocitos T/patología , Vértigo/etiologíaRESUMEN
STUDY DESIGN: Double-blind, randomised, multicentre study. OBJECTIVES: Efficacy and tolerability of propiverine extended-release (ER) compared with immediate-release (IR) were evaluated in patients with proven neurogenic detrusor overactivity (NDO). SETTING: Six Spinal Cord Injury Units located in Austria, Germany and Romania. METHODS: Propiverine ER 45 mg s.i.d. or IR 15 mg t.i.d. were administered in patients with proven NDO. Outcomes were assessed at baseline (V1), and after 21 days of treatment (V2): Reflex volume served as primary, leak point volume and maximum detrusor pressure as secondary efficacy outcomes, treatment-related adverse events as tolerability outcomes. RESULTS: Sixty-six patients with proven NDO were enrolled. Reflex volume (ml) increased significantly in the IR (V1: 100.9, V2: 202.9) and in the ER (V1: 89.8, V2: 180.3) group, no significant intergroup difference. Leak point volume increased, and maximum detrusor pressure decreased significantly in both groups, no significant intergroup differences. The percentage of patients presenting with incontinence was reduced by 14% in the IR and by 39% in the ER group, the difference is significant. Treatment-related adverse events manifested in 42 and 36% following propiverine IR and ER, respectively. CONCLUSION: The urodynamic efficacy outcomes demonstrated both galenic formulations to be equieffective. However, following propiverine ER 45 mg s.i.d. higher continence rates compared with propiverine IR 15 mg t.i.d. were achieved, possibly indicative of more balanced plasma-levels. A slight tendency for superior tolerability outcomes of propiverine ER compared with IR was demonstrated.
Asunto(s)
Bencilatos/administración & dosificación , Traumatismos de la Médula Espinal/complicaciones , Vejiga Urinaria Neurogénica/tratamiento farmacológico , Vejiga Urinaria Hiperactiva/tratamiento farmacológico , Agentes Urológicos/administración & dosificación , Adolescente , Adulto , Anciano , Preparaciones de Acción Retardada , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Vejiga Urinaria Neurogénica/etiología , Vejiga Urinaria Hiperactiva/etiología , Urodinámica , Adulto JovenRESUMEN
OBJECTIVE: To compare two new generation antimuscarinics at their recommended doses for treatment of overactive bladder syndrome (OAB). METHODS: A prospective, double blind, double-dummy, two-arm, parallel-group, 12-week study was conducted to compare the efficacy and safety of solifenacin 5 or 10 mg and tolterodine extended release (ER) 4 mg once daily in OAB patients. After 4 weeks of treatment patients had the option to request a dose increase but were dummied throughout as approved product labelling only allowed an increase for those on solifenacin. RESULTS: Solifenacin, with a flexible dosing regimen, showed greater efficacy to tolterodine in decreasing urgency episodes, incontinence, urge incontinence and pad usage and increasing the volume voided per micturition. More solifenacin treated patients became continent and reported improvements in perception of bladder condition assessments. The majority of side effects were mild to moderate in nature, and discontinuations were comparable and low in both groups. CONCLUSIONS: Solifenacin, with a flexible dosing regimen, was found to be superior to tolterodine ER with respect to the majority of the efficacy variables.
Asunto(s)
Compuestos de Bencidrilo/uso terapéutico , Cresoles/uso terapéutico , Antagonistas Muscarínicos/uso terapéutico , Fenilpropanolamina/uso terapéutico , Quinuclidinas/uso terapéutico , Tetrahidroisoquinolinas/uso terapéutico , Incontinencia Urinaria/tratamiento farmacológico , Análisis de Varianza , Compuestos de Bencidrilo/administración & dosificación , Cresoles/administración & dosificación , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Antagonistas Muscarínicos/administración & dosificación , Fenilpropanolamina/administración & dosificación , Estudios Prospectivos , Quinuclidinas/administración & dosificación , Succinato de Solifenacina , Tetrahidroisoquinolinas/administración & dosificación , Tartrato de Tolterodina , Resultado del TratamientoRESUMEN
The nephrotoxic side effect of Cis-platin was investigated in 38 patients with testicular tumors. The serum creatinine and the creatinine clearance served as function parameters. A temporary or permanent restriction of the creatinine clearance developed 31 of 38 patients during the therapy period. Increased creatinine levels were found in 6 patients. Two of them got into a chronic renal insufficiency. A pretherapeutic risk group of patients or a precarious dose of Cis-platin could not be found out.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Cisplatino/efectos adversos , Riñón/efectos de los fármacos , Neoplasias Testiculares/tratamiento farmacológico , Bleomicina/uso terapéutico , Cisplatino/uso terapéutico , Creatinina/sangre , Creatinina/orina , Ciclofosfamida/uso terapéutico , Dactinomicina/uso terapéutico , Humanos , Fallo Renal Crónico/inducido químicamente , Masculino , Neoplasias de Células Germinales y Embrionarias/tratamiento farmacológico , Vinblastina/uso terapéuticoRESUMEN
It has been reported that the antipsychotic drug, pimozide, is unique in that it blocks postsynaptic dopamine (DA) receptors, but not presynaptic DA receptors. This was examined by comparing pimozide with haloperidol for time of onset of action in several experimental paradigms designed to demonstrate blockade of pre- and postsynaptic striatal DA receptors. Haloperidol (1.0 mg/kg s.c.) caused near maximum catalepsy scores within 90 min after injection, a time when twice as much pimozide had yet to produce catalepsy. Pimozide consistently exhibited a delayed onset of action on several dopaminergic biochemical parameters including: increased striatal DA metabolism, increased DA receptors. In electrophysiological studies, pimozide did not block the ability of apomorphine to inhibit DA impulse flow if given 5 to 10 min before apomorphine, but was effective if longer pretreatment times were allowed. These data indicate that a delay or pimozide action occurs at both postsynaptic and presynaptic DA receptors. It is known that pimozide binds with high affinity to neuroleptic binding sites (in vitro) and rapidly enters the brain after systemic injection. Pretreatment of animals with SKF 525-A, an inhibitor of liver mixed-function oxidase enzymes, had little or no effect on pimoxide's actions, suggesting that formation of an active metabolite is not the cause of pimozide's delayed actions. The reason for the delayed action is unclear, but pimozide will interact with both pre- and postsynaptic DA receptors if given sufficient time.
Asunto(s)
Pimozida/farmacología , Receptores Dopaminérgicos/efectos de los fármacos , Receptores de Neurotransmisores/efectos de los fármacos , Animales , Apomorfina/farmacología , Catalepsia/inducido químicamente , Sinergismo Farmacológico , Femenino , Haloperidol/farmacología , Humanos , Oxigenasas de Función Mixta/antagonistas & inhibidores , Ratas , Tirosina 3-Monooxigenasa/metabolismo , Corteza Visual/fisiologíaRESUMEN
It has been previously reported that long-term tricyclic antidepressant treatment in the rat causes a subsensitivity of central beta-receptor-stimulated adenylate cyclase along with alterations of brain norepinephrine (NE) content and metabolism. We have confirmed earlier findings that after one week of desipramine treatment (5.0 mg/kg b.i.d.) brain NE levels decline while NE metabolism is similar to control animals, but is above control after 12 days of treatment. Single cell recordings from noradrenergic neurons of the locus coeruleus (LC) show that after one week of desipramine treatment, neuronal firing rate is lower than in control rats but greater than that seen in response to acutely administered drug. Furthermore, desipramine injection in a dose which profoundly altered LC impulse flow in control rats produced little or no effect on impulse flow in chronically treated rats. Of 25 or 250 microgram/kg doses of clonidine, which are equieffective for decreasing brain NE metabolism in control animals, only the larger dose decreased NE metabolism in 12 day desipramine-treated rats. The postsynaptic alpha-antagonist prazosin (5.0 mg/kg) increased NE metabolism in both groups. These results suggest that presynaptic (alpha 2) adrenoreceptors become subsensitive during long-term desipramine treatment, thus allowing recovery of noradrenergic impulse flow in the presence of NE uptake inhibition.